Molecular mechanisms of head and neck cancer

Drug Discovery Today: Disease Mechanisms

Volumn 1, Issue 2, 2004, Pages 273-281

  Figueiredo, Marxa L ^a   Kim, Yong ^a   Zhou, Xiaofeng C ^a   Myers, Jeffrey N ^b   Wong, David D T ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [N (2 HYDROXYETHYL) N [2 (3 INDOLYL)ETHYL]AMINOMETHYL]CINNAMOHYDROXAMIC ACID; 7 HYDROXYSTAUROSPORINE; ADVEXIN; ANTINEOPLASTIC AGENT; AP 23573; BEXAROTENE; BORTEZOMIB; CARBOPLATIN; CELECOXIB; CETUXIMAB; CISPLATIN; CURCUMIN; ERLOTINIB; FLAVOPIRIDOL; FR 901228; GEFITINIB; IGN 221; IMATINIB; IMC 225; ISOTRETINOIN; KOS 953; LGD 1550; LONAFARNIB; MONOCLONAL ANTIBODY; ONYX 015; PELITINIB; PERIFOSINE; PROTEIN TYROSINE KINASE INHIBITOR; R 11577; TARGETRIN; TEMSIROLIMUS; TIPIFARNIB; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ANEMIA; ANGIOGENESIS; ANOREXIA; APOPTOSIS; CARCINOGENESIS; CELL INVASION; CELL PROLIFERATION; CHILL; CLINICAL TRIAL; DIARRHEA; DNA REPAIR; DRUG BIOAVAILABILITY; DRUG HALF LIFE; EDEMA; FATIGUE; FEVER; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; GENE MUTATION; GRANULOCYTOPENIA; HEAD AND NECK CANCER; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPOCALCEMIA; HYPOTHYROIDISM; HYPOXEMIA; INJECTION PAIN; LEUKOPENIA; LIVER TOXICITY; MUCOSA INFLAMMATION; MUSCLE CRAMP; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; NONHUMAN; PNEUMOTHORAX; PROGNOSIS; PRURITUS; RASH; REVIEW; SIGNAL TRANSDUCTION; SKIN MANIFESTATION; SQUAMOUS CELL CARCINOMA; STOMACH PAIN; SURVIVAL RATE; THROMBOCYTOPENIA;

EID: 23744509484     PISSN: 17406765     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddmec.2004.10.003     Document Type: Review

References (60)

1. Jemal, A. et al. (2004) Cancer statistics. CA Cancer J. Clin. 54, 8-29
2. Grandis, J.R. and Tweardy, D.J. (1993) Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res. 53, 3579-3584
3. Mendelsohn, J. and Baselga, J. (2003) Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J. Clin. Oncol. 21, 2787-2799
4. Bonner, J.A. et al. (2004) Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: a phase III study of high dose radiation therapy with or without cetuximab. In Proceedings of the 2004 Americal Society of Clinical Oncology Annual Meeting (Vol. abstract 5507)
5. Cohen, E.E. et al. (2002) Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J. Clin. Oncol. 21, 1980-1987
6. Soulieres, D. et al. (2004) Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J. Clin. Oncol. 22, 77-85
7. Hahn, S.M. et al. (2002) A Phase I trial of the farnesyltransferase inhibitor L-778,123 and radiotherapy for locally advanced lung and head and neck cancer. Clin. Cancer Res. 8, 1065-1072
8. Sumitani, K. et al. (2001) Specific inhibition of cyclooxygenase-2 results in inhibition of proliferation of oral cancer cell lines via suppression of prostaglandin E2 production. J. Oral. Pathol. Med. 30, 41-47
9. Pai, R. et al. (2002) Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat. Med. 8, 289-293
10. Zweifel, B.S. et al. (2002) Direct evidence for a role of cyclooxygenase 2-derived prostaglandin E2 in human head and neck xenograft tumors. Cancer Res. 62, 6706-6711
11. Aggarwal, B.B. et al. (2003) Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res. 23, 363-398
12. Cheng, A.L. et al. (2001) Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res. 21, 2895-2900
13. Aghajanian, C. et al. (2002) A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin. Cancer Res. 8, 2505-2511
14. Nagpal, J. et al. (2002) Activation of Stat-3 as one of the early events in tobacco chewing-mediated oral carcinogenesis. Cancer 94, 2393-2400
15. Grandis, J.R. et al. (2000) Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proc. Natl. Acad. Sci. USA 97, 4227-4232
16. Shen, Y. et al. (2001) Constitutively activated Stat3 protects fibroblasts from serum withdrawal and UV-induced apoptosis and antagonizes the proapoptotic effects of activated Stat1. Proc. Natl. Acad. Sci. USA 98, 1543-1548
17. Aoki, Y. et al. (2003) Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. Blood 101, 1535-1542
18. Leong, P.L. et al. (2003) Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth. Proc. Natl. Acad. Sci. USA 100, 4138-4143
19. Sherr, C.J. (1996) Cancer cell cycles. Science 274, 1672-1677
20. Sherr, C.J. and Roberts, J.M. (1999) CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 13, 1501-1512
21. Todd, R. et al. (1995) Deleted in oral cancer-1 (doc-1), a novel oral tumor suppressor gene. FASEB J. 9, 1362-1370
22. Zhang, X. et al. (1999) Identification and mutation analysis of DOC-1R, a DOC-1 growth suppressor-related gene. Biochem. Biophys. Res. Commun. 255, 59-63
23. Senderowicz, A.M. and Sausville, E.A. (2000) Preclinical and clinical development of cyclin-dependent kinase modulators. J. Natl. Cancer Inst. 92, 376-387
24. Patel, V. et al. (1998) Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis. J. Clin. Invest. 102, 1674-1681
25. Tamaoki, T. (1991) Use and specificity of staurosporine, UCN-01, and calphostin C as protein kinase inhibitors. Methods Enzymol. 201, 340-347
26. Senderowicz, A.M. (2003) Small-molecule cyclin-dependent kinase modulators. Oncogene 22, 6609-6620
27. Brennan, J.A. et al. (1995) Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 332, 712-717
28. Koch, W.M. et al. (1996) p53 mutation and locoregional treatment failure in head and neck squamous cell carcinoma. J. Natl. Cancer Inst. 88, 1580-1586
29. Shin, D.M. et al. (2000) Biochemopreventive therapy for patients with premalignant lesions of the head and neck and p53 gene expression. J. Natl. Cancer Inst. 92, 69-73
30. Nielsen, L.L. et al. (1998) Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer. Clin. Cancer Res. 4, 835-846
31. Clayman, G.L. et al. (1998) Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. J. Clin. Oncol. 16, 2221-2232
32. Gurnani, M. et al. (1999) Adenovirus-mediated p53 gene therapy has greater efficacy when combined with chemotherapy against human head and neck, ovarian, prostate, and breast cancer. Cancer Chemother. Pharmacol. 44, 143-151
33. Khuri, F.R. et al. (2000) a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat. Med. 6, 879-885
34. Moon, C. et al. (2003) Current status of gene therapy for lung cancer and head and neck cancer. Clin. Cancer Res. 9, 5055-5067
35. Mehta, K. et al. (1996) Activation of retinoid receptors RAR alpha and RXR alpha induces differentiation and apoptosis, respectively, in HL-60 cells. Cell Growth Differ. 7, 179-186
36. Rizvi, N.A. et al. (1999) A Phase I study of LGD1069 in adults with advanced cancer. Clin. Cancer Res. 5, 1658-1664
37. Papadimitrakopoulou, V.A. and Hong, W.K. (1997) Retinoids in head and neck chemoprevention. Proc. Soc. Exp. Biol. Med. 216, 283-290
38. Saito, A. et al. (1999) A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc. Natl. Acad. Sci. USA 96, 4592-4597
39. Agnew, E.B. et al. (2001) Measurement of the novel antitumor agent 17-(allylamino)-17-demethoxygeldanamycin in human plasma by high-performance liquid chromatography. J. Chromatogr. B Biomed. Sci. Appl. 755, 237-243
40. Fingar, D.C. and Blenis, J. (2004) Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 23, 3151-3171
41. Kim, E.S. et al. (2004) Cetuximab in cancers of the lung and head & neck. Semin. Oncol. 31 (Suppl. 1), 61-67
42. Caponigro, F. (2004) Rationale and clinical validation of epidermal growth factor receptor as a target in the treatment of head and neck cancer. Anticancer Drugs 15, 311-320
43. Khuri, F.R. and Jain, S.R. (2004) Novel agents and incremental advances in the treatment of head and neck cancer. Semin. Oncol. 31 (Suppl. 4), 3-10
44. Smith, J.K. et al. (2004) Emerging roles of targeted small molecule protein-tyrosine kinase inhibitors in cancer therapy. Oncol. Res. 14, 175-225
45. Patnaik, A. et al. (2003) A phase I, pharmacokinetic, and biological study of the farnesyltransferase inhibitor tipifarnib in combination with gemcitabine in patients with advanced malignancies. Clin. Cancer Res. 9, 4761-4771
46. Sparreboom, A. et al. (2004) Phase I and pharmacokinetic study of irinotecan in combination with R115777, a farnesyl protein transferase inhibitor. Br. J. Cancer 90, 1508-1515
47. Rudin, C.M. et al. (2003) An attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant oral dysplasia. J. Clin. Oncol. 21, 4546-4552
48. Merritt, J.A. et al. (2001) Clinical evaluation of adenoviral-mediated p53 gene transfer: review of INGN 201 studies. Semin. Oncol. 28 (Suppl. 16), 105-114
49. Patel, S.D. et al. (2000) The p53-independent tumoricidal activity of an adenoviral vector encoding a p27-p16 fusion tumor suppressor gene. Mol. Ther. 2, 161-169
50. Kelland, L.R. (2000) Flavopiridol, the first cyclin-dependent kinase inhibitor to enter the clinic: current status. Expert Opin. Investig. Drugs 9, 2903-2911
51. Goetz, M.P. et al. (2003) The Hsp90 chaperone complex as a novel target for cancer therapy. Ann. Oncol. 14, 1169-1176
52. Kamal, A. et al. (2004) Therapeutic and diagnostic implications of Hsp90 activation. Trends Mol. Med. 10, 283-290
53. Wieder, R. et al. (2002) Phase I/II trial of accutane as a potentiator of carboplatin and paclitaxel in squamous cell carcinomas. Am. J. Clin. Oncol. 25, 447-450
54. Soignet, S.L. et al. (2000) Initial clinical trial of a high-affinity retinoic acid receptor ligand (LGD 1550). Clin. Cancer Res. 6, 1731-1735
55. Huang, S. and Houghton, P.J. (2003) Targeting mTOR signaling for cancer therapy. Curr. Opin. Pharmacol. 3, 371-377
56. Sawyers, C.L. (2003) Will mTOR inhibitors make it as cancer drugs? Cancer Cell 4, 343-348
57. Clackson, T. et al. (2003) Broad anti-tumor activity of ap23573, an mTOR inhibitor in clinical development. In Proceedings of the 2003 ASCO Annual Meeting (Vol. 22), p. 220, American Society of Clinical Oncology
58. Peralba, J.M. et al. (2003) Pharmacodynamic evaluation of CCI-779, an inhibitor of mTOR, in cancer patients. Clin. Cancer Res. 9, 2887-2892
59. Sandor, V. et al. (2002) Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin. Cancer Res. 8, 718-728
60. Marshall, J.L. et al. (2002) A phase I trial of depsipeptide (FR901228) in patients with advanced cancer. J. Exp. Ther. Oncol. 2, 325-332